CytoDyn, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.cytodyn.com
Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection
Phase 2
Completed
- Conditions
- HIV -1 InfectionHIV Infections
- Interventions
- Drug: PRO 140 (humanized monoclonal antibody to CCR5)Drug: Placebo Comparator
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00642707
- Locations
- ๐บ๐ธ
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
PRO 140 by IV Administration in Adults With HIV-1 Infection
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00613379
- Locations
- ๐บ๐ธ
Progenics Pharmaceuticals, Inc, Tarrytown, New York, United States
Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
- First Posted Date
- 2005-05-11
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00110591
- Locations
- ๐บ๐ธ
MDS Pharma Services, Lincoln, Nebraska, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath